John C. Thomas - 25 Jun 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Reporting relationship: EVP, General Counsel
Issuer ticker: KRYS
Reported as of: 25 Jun 2026
Net transaction value: -$347,270
SEC form: 4
Accepted by SEC: 26 Jun 2026, 18:45:51 UTC
Prior SEC filing: 27 May 2026
Source filing: View source filing
Reporting owner signature: /s/ John C. Thomas

Key filing fact

John C. Thomas filed Form 4 for Krystal Biotech, Inc. (KRYS) on 26 Jun 2026.

Key facts

This page summarizes John C. Thomas's Form 4 filing for Krystal Biotech, Inc. (KRYS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2026, 18:45.

Change

Previous filing in this sequence was filed on 27 May 2026.
Current net transaction value: -$347,270.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002114900 Primary reporting owner

Thomas John Charles

Relationship: EVP, General Counsel
Address: C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
Signature: /s/ John C. Thomas
Signature date: 26 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KRYS transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,000
Change %
Price: $179.25^*
Shares after: 1,000
Date: 25 Jun 2026
Ownership: Direct
Footnotes: F1

KRYS transaction

Common Stock

Sale

Transaction value: $347,270
Shares: -1,000
Change %: -100%
Price: $347.27
Shares after: 0
Date: 25 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KRYS transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -1,000
Change %: -13%
Price: $0.000000^*
Shares after: 6,500
Date: 25 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $179.25
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.

Footnote F2

The options vest ratably over a four-year period beginning on February 28, 2026.